Click the JOIN button if you think you might be eligible for this study. Company Please complete the form below with your contact information. By completing this form, you are providing your permission (consent) for research professionals to contact you about active or future studies and health research news. Email Address * First Name * Last Name
The purpose of this study is to investigate the effect of balcinrenone/dapagliflozin compared with dapagliflozin, on the risk of CV death, HF event with and without hospitalisation, in patients with chronic HF, impaired kidney function, and who have had a recent HF event.
Click the JOIN button if you think you might be eligible for this study. Email Please complete the form below with your contact information. By completing this form, you are providing your permission (consent) for research professionals to contact you about active or future studies and health research news. Email Address * First Name * Last Name
Click the JOIN button if you think you might be eligible for this study. Phone Please complete the form below with your contact information. By completing this form, you are providing your permission (consent) for research professionals to contact you about active or future studies and health research news. Email Address * First Name * Last Name
Click the JOIN button if you think you might be eligible for this study. Phone Please complete the form below with your contact information. By completing this form, you are providing your permission (consent) for research professionals to contact you about active or future studies and health research news. Email Address * First Name * Last Name
A recent study conducted by researchers from Stanford Medicine, published in JAMA Network Open, reveals that adopting a vegan diet can lead to significant improvements in cardiovascular health within just eight weeks. The study, unique for its focus on identical twins, aimed to eliminate genetic and lifestyle variations that often complicate diet research. Involving 44
This clinical research study is being conducted to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits.
The main purpose of this study is to evaluate the safety and efficacy of a once-weekly, experimental medication for participants who have obesity or are overweight and have established cardiovascular disease. The study will last about 113 weeks.
Company Do you suffer from Obesity? Obesity and being overweight are leading factors in the development of heart disease and stroke, as well as Type 2 diabetes. More than 10 million Canadians are overweight, while another 7 million Canadians are considered obese. If you are overweight, you are at high risk of becoming obese, which
Twitter The diagnosis of heart failure is increasing throughout the world. It is a serious condition that severely impacts quality of life. Patients with heart failure have difficult or labored breathing; are fatigued; have lung congestion and fluid retention. They frequently require hospitalisation for their condition. New and better medications are needed to treat this
